Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37.

McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL.

Antimicrob Agents Chemother. 2011 Jun;55(6):2897-904. doi: 10.1128/AAC.00016-11. Epub 2011 Apr 4.

2.

Role of the HefC efflux pump in Helicobacter pylori cholesterol-dependent resistance to ceragenins and bile salts.

Trainor EA, Horton KE, Savage PB, Testerman TL, McGee DJ.

Infect Immun. 2011 Jan;79(1):88-97. doi: 10.1128/IAI.00974-09. Epub 2010 Oct 25.

3.

The lipid A 1-phosphatase of Helicobacter pylori is required for resistance to the antimicrobial peptide polymyxin.

Tran AX, Whittimore JD, Wyrick PB, McGrath SC, Cotter RJ, Trent MS.

J Bacteriol. 2006 Jun;188(12):4531-41.

4.

Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa.

Cullen TW, Giles DK, Wolf LN, Ecobichon C, Boneca IG, Trent MS.

PLoS Pathog. 2011 Dec;7(12):e1002454. doi: 10.1371/journal.ppat.1002454. Epub 2011 Dec 22.

5.

Helicobacter pylori Resists the Antimicrobial Activity of Calprotectin via Lipid A Modification and Associated Biofilm Formation.

Gaddy JA, Radin JN, Cullen TW, Chazin WJ, Skaar EP, Trent MS, Algood HM.

MBio. 2015 Dec 8;6(6):e01349-15. doi: 10.1128/mBio.01349-15.

6.

Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.

Yakoob J, Abbas Z, Usman MW, Awan S, Naz S, Jafri F, Hamid S, Jafri W.

Microb Drug Resist. 2014 Aug;20(4):305-9. doi: 10.1089/mdr.2013.0086. Epub 2013 Jul 11.

PMID:
23844851
7.
8.

Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

LeszczyƄska K, Namiot A, Fein DE, Wen Q, Namiot Z, Savage PB, Diamond S, Janmey PA, Bucki R.

BMC Microbiol. 2009 Sep 3;9:187. doi: 10.1186/1471-2180-9-187.

9.

The actions of bismuth in the treatment of Helicobacter pylori infection.

Lambert JR, Midolo P.

Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:27-33. Review.

10.

Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.

Graham DY, Saeed MA, Hoffman J, El-Zimaity HM, Kwon DH, Osato MS.

Aliment Pharmacol Ther. 2001 Apr;15(4):513-8.

11.

Phosphoethanolamine Transferase LptA in Haemophilus ducreyi Modifies Lipid A and Contributes to Human Defensin Resistance In Vitro.

Trombley MP, Post DM, Rinker SD, Reinders LM, Fortney KR, Zwickl BW, Janowicz DM, Baye FM, Katz BP, Spinola SM, Bauer ME.

PLoS One. 2015 Apr 22;10(4):e0124373. doi: 10.1371/journal.pone.0124373. eCollection 2015.

12.

Helicobacter pylori's cholesterol uptake impacts resistance to docosahexaenoic acid.

Correia M, Casal S, Vinagre J, Seruca R, Figueiredo C, Touati E, Machado JC.

Int J Med Microbiol. 2014 May;304(3-4):314-20. doi: 10.1016/j.ijmm.2013.11.018. Epub 2013 Dec 1.

13.

Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.

Mobley HL, Garner RM, Chippendale GR, Gilbert JV, Kane AV, Plaut AG.

Helicobacter. 1999 Sep;4(3):162-9.

PMID:
10469190
14.

Role of antimicrobial peptides expressed by host cells upon infection by Helicobacter pylori.

Gopal R, Jeong E, Seo CH, Park Y.

Protein Pept Lett. 2014;21(10):1057-64. Review.

PMID:
25001211
15.

Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.

Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ.

Helicobacter. 2000 Sep;5(3):176-82.

PMID:
10971684
16.

Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro.

Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE.

Antimicrob Agents Chemother. 2000 Feb;44(2):248-54.

17.

Haemophilus ducreyi SapA contributes to cathelicidin resistance and virulence in humans.

Mount KL, Townsend CA, Rinker SD, Gu X, Fortney KR, Zwickl BW, Janowicz DM, Spinola SM, Katz BP, Bauer ME.

Infect Immun. 2010 Mar;78(3):1176-84. doi: 10.1128/IAI.01014-09. Epub 2010 Jan 19.

18.

Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.

Chiba N.

Can J Gastroenterol. 2000 Nov;14(10):885-9.

PMID:
11111112
19.

The Helicobacter pylori Mfd protein is important for antibiotic resistance and DNA repair.

Lee GH, Jeong JY, Chung JW, Nam WH, Lee SM, Pak JH, Choi KD, Song HJ, Jung HY, Kim JH.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):454-6. doi: 10.1016/j.diagmicrobio.2009.08.007. Epub 2009 Sep 18.

PMID:
19766427
20.

Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori.

Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF.

Gastroenterology. 2003 Dec;125(6):1613-25.

PMID:
14724813

Supplemental Content

Support Center